ClinicalTrials.gg
RecruitingNCT05700825Updated Oct 8, 2026

Rehabilitation of Airway Protection in Parkinson's Disease

A Phase 2 interventional study of Expiratory Muscle Strength Training + Cough Skill Training in Parkinson Disease and Dysphagia, sponsored by Teachers College, Columbia University. Recruiting at 2 sites in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Teachers College, Columbia University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2022, registered Dec 2022).
  • Started Aug 2022; still recruiting 4 years 3 months later.
Updated Oct 8, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
231st of 1,257
120 · median 36
Started
2022
with 104 others
Phase 2
234 of 1,650
25 open now
Primary completion
2027-09
later than 206 of 384 live
Registered
1,324th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 231st largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 105 that started in 2022, is one of 234 in phase 2, reaches primary completion later than 206 of the 384 other live ones, and was the 1,324th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical deficits. The investigators will examine the comparative effectiveness of a novel treatment paradigm delivered in-person versus via telehealth in persons with PD, as well as the role of patient burden and treatment adherence on outcomes; thus, the proposed research is relevant to public health and in line with NIH's mission to identify novel, efficacious, and accessible rehabilitation strategies for short- and long-term improvement of dysfunctional airway protection in PD.

Read the detailed description

Progressive disorders of airway protection, such as swallowing disorders (dysphagia) and cough disorders (dystussia), are highly prevalent in PD and have significant negative implications for health and quality of life. In fact, aspiration pneumonia, commonly associated with dysphagia/dystussia, is a leading cause of death in PD. Despite this, there is currently no established standard of care for the treatment of airway protective disorders in this population. Even more critically, approximately 40% of individuals with PD in the United States do not access rehabilitation services or receive specialized care for these potentially life-threatening airway protective deficits. Expiratory Muscle Strength Training (EMST) and Cough Skill Training (CST) have been found to improve airway protective disorders in PD and be feasible via telehealth. However, a significant clinical-research gap remains in that it has not been demonstrated that clinical outcomes are comparable (non-inferior) when these treatments are delivered via telehealth versus in-person. This gap limits access to these important services with detrimental effects to health and quality of life. The long-term goal of this line of research is to improve the health outcomes of individuals with PD, specifically as they relate to airway protective dysfunction. The objective of this application is to pair EMST + CST - and compare clinical and patient-centered outcomes when conducted in-person versus via telehealth in the short- and the long-term. Also, the investigators will assess the role of specific patient burden factors and resultant treatment adherence on clinical outcomes. Therefore, the aims of this study are to: 1) Compare clinical and patient-centered outcomes following four weeks of intensive in-person vs. telehealth EMST+CST treatment in persons with PD, 2) Compare clinical and patient-centered outcomes from a long-term EMST+CST maintenance program offered in-person vs. via telehealth in persons with PD, and 3) Identify the role of specific patient burden factors (i.e., geographic location, cognitive function, disease severity, and caregiver burden) on treatment adherence in the short- and long-term and the influence of treatment adherence on clinical outcomes. The investigators will achieve these aims by conducting a two-arm, two site, randomized clinical trial in 120 people with PD comparing in-person vs. telehealth EMST+CST treatment after a four-week intensive period (aim1) and after a one year maintenance treatment period (with assessments at six and 12 months - aim 2). The investigators anticipate our findings will result in immediately translatable clinical deliverables that will have broad impact for reduced burden and improved accessibility of treatment. Further, these findings will inform our future studies investigating these treatments and service delivery models on long-term outcomes (i.e., aspiration pneumonia, hospitalization, death), accessibility, and healthcare costs.

03

Conditions studied

  • Parkinson Disease
  • Dysphagia
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with PD (Hoehn and Yahr Stages II-IV)126,127 confirmed by a Movement Disorders fellowship trained neurologist having reviewed the video recorded Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assessment for each participant and using strict UK brain bank criteria
  • airway protective deficits as defined as a minimum of penetration of thin liquids (penetration-aspiration score>3) as determined by instrumental swallowing assessment and/or dystussia as determined by voluntary cough assessment (PEFR ≤4.1 L/s)
  • not actively receiving exercise-based swallowing therapy
  • between the ages of 50 and 90.

Exclusion criteria

Exclusion criteria:

  • Other neurological disorders (e.g., multiple sclerosis, stroke, brain tumor, etc.)
  • history of head and neck cancer
  • history of breathing disorders or diseases (e.g., )
  • history of smoking in the last five years
  • uncontrolled hypertension
  • difficulty complying due to neuropsychological dysfunction (i.e., severe depression with >28 on the Beck Depression Index (BDI-II), dementia with \<19 on the (MoCA))
  • allergy to capsaicin or barium
  • further than 1.5 hours (door to door) distance from either Teachers College, Columbia University or Purdue University.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    In-person

    Behavioral: Expiratory Muscle Strength Training + Cough Skill Training

  • Experimental
    Telehealth

    Behavioral: Expiratory Muscle Strength Training + Cough Skill Training

Interventions

  • BehavioralExpiratory Muscle Strength Training + Cough Skill Training

    Expiratory Muscle Strength Training (EMST). EMST is a widely used and efficacious treatment approach that uses a calibrated device with a one-way, spring-loaded pressure relief valve to mechanically overload the expiratory and submental muscles. Cough Skill Training (CST) involves a digital peak flow meter device which measures PEFR (peak expiratory flow rate) in liters/second and allows patients to receive immediate biofeedback.

06

What researchers measure

Primary outcomes

  1. Change in Peak Expiratory Flow Rate (Cough PEFR) - phase 1

    Time frame: Pretraining to posttraining (after four weeks of intensive training)

  2. Change in Peak Expiratory Flow Rate (Cough PEFR) - phase 2

    Time frame: post-training to post one-year maintenance

  3. Change in Penetration-Aspiration Scale (PAS) - phase 1

    PAS, max value: 8 (most impaired), min value 1 (least impaired).

    Time frame: Pretraining to posttraining (after four weeks of intensive training)

  4. Change in Penetration-Aspiration Scale (PAS) - phase 2

    PAS, max value: 8 (most impaired), min value 1 (least impaired).

    Time frame: post-training to post one-year maintenance

Secondary outcomes

  1. Change in Maximum Expiratory Pressure - phase 1

    Time frame: Pretraining to posttraining (after four weeks of intensive training)

  2. Change in Maximum Expiratory Pressure - phase 2

    Time frame: post-training to post one-year maintenance

  3. Change in Cough expired volume - phase 1

    Time frame: Pretraining to posttraining (after four weeks of intensive training)

  4. Change in Cough expired volume - phase 2

    Time frame: post-training to post one-year maintenance

  5. Treatment Adherence - phase 1

    percent of prescribed training coughs and breaths completed

    Time frame: posttraining (after four weeks of intensive training)

  6. Change in Treatment Adherence- phase 2

    percent of prescribed training coughs and breaths completed

    Time frame: post-training to post one-year maintenance

  7. Change in SWAL-QOL- phase 1

    self-report questionnaire of swallowing quality of life, 44 min score, 220 max score - higher score is better QOL

    Time frame: Pretraining to posttraining (after four weeks of intensive training)

  8. Change in SWAL-QOL - phase 2

    self-report questionnaire of swallowing quality of life, 44 min score, 220 max score - higher score is better QOL

    Time frame: post-training to post one-year maintenance

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Sep 2027, 60 months after the start.

Of 106 non-industry phase 2 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 60 months is above that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2022
First posted
Jan 26, 2023
StartActual
Aug 11, 2022
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (1 now active, not recruiting, 1 now recruiting)
Show 2 sites
  • Purdue University · West Lafayette, United StatesRecruiting→Active, not recruiting
  • Teachers College, Columbia University · New York, United StatesActive, not recruiting→Recruiting
Oct 8, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Purdue University · West Lafayette, United StatesContact removed m•••@purdue.edu
  • Teachers College, Columbia University · New York, United StatesContact added m•••@tc.columbia.edu · •••3072
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    2 sites changed recruiting status (1 now active, not recruiting, 1 now recruiting)
    Show 2 sites
    • Purdue University · West Lafayette, United StatesRecruiting→Active, not recruiting
    • Teachers College, Columbia University · New York, United StatesActive, not recruiting→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Purdue University · West Lafayette, United StatesContact removed m•••@purdue.edu
    • Teachers College, Columbia University · New York, United StatesContact added m•••@tc.columbia.edu · •••3072
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05700825
Lead sponsor
Teachers College, Columbia University
Responsible party
Michelle Troche (Professor, Principle Investigator, Teachers College, Columbia University) — Principal investigator
First posted
Jan 26, 2023
Start date
Aug 11, 2022
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Michelle Troche, PhD
Contact
uadlab@tc.columbia.edu
212-678-3072
Michelle Troche, PhD
principal investigator · Teachers College, Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion